WHO Does What It Warned: Delists Shantha Biotech's Pentavalent Vaccine Shan5; More Pains For Sanofi-Aventis?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a move that could in the short term severely impair the reputation of Hyderabad-based vaccines maker Shantha Biotechnics, now part of Sanofi-Aventis, the World Health Organization has delisted its popular pentavalent vaccine Shan5, which is used by scores of nations as part of their national immunization programs for the prevention against deadly diseases like diphtheria, tetanus, hepatitis B and Hib
You may also be interested in...
No Cease-Fire: India Seeks $190 Million Tax From Sanofi’s Shantha Deal
India’s tax department has filed a petition with the Supreme Court, challenging an earlier judgment that sided with Sanofi in a tax dispute that could impact future acquisitions in the country.
No Cease Fire: India Seeks $190 Million Tax From Sanofi’s Shantha Deal
India’s tax department has filed a petition with the Supreme Court, challenging an earlier judgment that sided with Sanofi in a tax dispute that could impact future acquisitions in the country.
WHO Nod To India’s Regulatory System A Booster For Vaccine Makers
Indian vaccine makers see the latest move to qualify the Indian regulatory system as an opportunity to pump up exports.